Brief: Promis Neurosciences Doses First Subjects In Phase 1A Clinical Trial To Treat Alzheimer’s Disease
20/11/2023 12:27
Nov 20 (Reuters) - ProMIS Neurosciences Inc PMN.O :
* PROMIS NEUROSCIENCES DOSES FIRST SUBJECTS IN PHASE 1A
CLINICAL
TRIAL OF PMN310 TO TREAT ALZHEIMER’S DISEASE
* PROMIS NEUROSCIENCES INC: EXPECT TO HAVE INITIAL SAFETY
AND
PHARMACOKINETIC (PK) DATA TO SHARE IN FIRST HALF OF 2024
Source text for Eikon: ID:nGNX7ljK2z
Further company coverage: PMN.O
((Reuters.Briefs@thomsonreuters.com;))